Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

BACKGROUND: Anaplastic lymphoma kinase (ALK) fusions need to be accurately and efficiently detected for ALK inhibitor therapy. Fluorescence in situ hybridization (FISH) remains the reference test. Although increasing data are supporting that ALK immunohistochemistry (IHC) is highly concordant with F...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, K., Togashi, Y., Kamihara, Y., Fukuyama, T., Yoshioka, H., Inoue, A., Katsuki, H., Kiura, K., Nakagawa, K., Seto, T., Maemondo, M., Hida, T., Harada, M., Ohe, Y., Nogami, N., Yamamoto, N., Nishio, M., Tamura, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684157/
https://www.ncbi.nlm.nih.gov/pubmed/26487585
http://dx.doi.org/10.1093/annonc/mdv501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684157/
https://www.ncbi.nlm.nih.gov/pubmed/26487585
http://dx.doi.org/10.1093/annonc/mdv501

Ejemplares similares